MedTrace Logo

the Serum Metabolite Based PrecogColo Dx Test for Advanced Colorectal Neoplasia Screening

NCT05870696 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2023-05-23

No results posted yet for this study

Summary

This study is to Evaluate the diagnostic sensitivity of the serum metabolite based PrecogColo Dx test for advanced colorectal neoplasia Screening, including advanced adenoma and colorectal cancer. There are two steps in this study. Firstly, the diagnostic model is established based on tumor-specific and gut-microbiome related serum metabolites. Secondly, the sensitivity, specificity and accuracy of the diagnostic model is evaluated in detecting advanced adenoma and colorectal cancer stages in an independent multi-centered cohort.

Conditions

  • Colorectal Adenoma

Interventions

DIAGNOSTIC_TEST

PrecogColo Dx test

the serum metabolite based PrecogColo Dx test for advanced colorectal neoplasia Screening, including advanced adenoma and colorectal cancer

Sponsors & Collaborators

  • Peking University Third Hospital

    lead OTHER

Principal Investigators

  • shigang ding, doctor · Peking University Third Hospital

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-30
Primary Completion
2024-02-27
Completion
2024-02-27

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05870696 on ClinicalTrials.gov